• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.

作者信息

Suarez-Kelly Lorena P, Levine Kala M, Olencki Thomas E, Del Campo Sara E Martin, Streacker Elizabeth A, Brooks Taylor R, Karpa Volodymyr I, Markowitz Joseph, Bingman Anissa K, Geyer Susan M, Kendra Kari L, Carson William E

机构信息

Comprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA.

Medical Oncology, Department of Internal Medicine, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA.

出版信息

Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6.

DOI:10.1007/s00262-019-02308-w
PMID:30725205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6447692/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/054a6bf255c2/262_2019_2308_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/df03c6cc280b/262_2019_2308_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/9b51630562ea/262_2019_2308_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/bf2319d67301/262_2019_2308_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/054a6bf255c2/262_2019_2308_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/df03c6cc280b/262_2019_2308_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/9b51630562ea/262_2019_2308_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/bf2319d67301/262_2019_2308_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1489/11028384/054a6bf255c2/262_2019_2308_Fig4_HTML.jpg

相似文献

1
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.高危黑色素瘤辅助治疗中干扰素-α-2b剂量降低的一项初步研究。
Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6.
2
Adjuvant interferon treatment for melanoma.黑色素瘤的辅助干扰素治疗。
Hematol Oncol Clin North Am. 1998 Aug;12(4):823-33. doi: 10.1016/s0889-8588(05)70025-3.
3
[Current position of the Professional Group of Dermatologic Oncology on high dosage therapy with interferon-alpha-2b].[皮肤肿瘤学专业组关于干扰素α-2b高剂量疗法的当前立场]
Hautarzt. 2000 May;51(5):360-2. doi: 10.1007/s001050051135.
4
Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.静脉注射大剂量干扰素 alfa-2b 治疗可减少黑色素瘤患者循环中的调节性 T 细胞。
Clin Exp Metastasis. 2012 Oct;29(7):801-5. doi: 10.1007/s10585-012-9504-2. Epub 2012 Jul 1.
5
Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.可切除的III期黑色素瘤患者的辅助治疗：高剂量干扰素-α与伊匹单抗联合激酶抑制剂的比较。
Tumori. 2012 Mar-Apr;98(2):185-90. doi: 10.1177/030089161209800202.
6
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.低剂量干扰素α-2b联合或不联合改良高剂量干扰素α-2b诱导期用于淋巴结阴性黑色素瘤患者的前瞻性随机多中心辅助皮肤科肿瘤协作组试验。
J Clin Oncol. 2009 Jul 20;27(21):3496-502. doi: 10.1200/JCO.2008.21.3892. Epub 2009 May 11.
7
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].强化静脉注射干扰素α-2b与ECOG 1684方案作为Ⅲ期黑色素瘤辅助治疗的耐受性：一项意大利黑色素瘤多中心随机Ⅲ期试验（IMI-Mel.A.）[ISRCTN75125874]
BMC Cancer. 2006 Feb 27;6:44. doi: 10.1186/1471-2407-6-44.
8
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.辅助性帕博利珠单抗对比大剂量干扰素 α-2b 治疗中国 III 期黑色素瘤切除术后患者的回顾性队列研究。
Invest New Drugs. 2020 Oct;38(5):1334-1341. doi: 10.1007/s10637-020-00913-6. Epub 2020 Feb 18.
9
Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.α干扰素信号传导及其与恶性黑色素瘤患者抗原加工相关转运蛋白（TAP）上调作用的相关性。
PLoS One. 2016 Jan 6;11(1):e0146325. doi: 10.1371/journal.pone.0146325. eCollection 2016.
10
Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.晚期恶性黑色素瘤联合化疗加或不加αN1干扰素（IFN）——一项随机III期试点研究。
Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:310-4.

引用本文的文献

1
Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategies in patients with pancreatic cancer.胰腺癌患者基于干扰素-γ信号的个性化异质性及治疗策略的鉴定与表征
Front Oncol. 2023 Oct 24;13:1227606. doi: 10.3389/fonc.2023.1227606. eCollection 2023.
2
Dichotomous Nitric Oxide-Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma.STAT1的二分法一氧化氮依赖性翻译后修饰与伊匹单抗治疗黑色素瘤的疗效相关。
Cancers (Basel). 2023 Mar 14;15(6):1755. doi: 10.3390/cancers15061755.
3
Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.

本文引用的文献

1
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.辅助达拉非尼联合曲美替尼治疗 BRAF 突变型 III 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
2
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.权衡免疫检查点抑制剂在黑色素瘤治疗中的利弊。
Immunotherapy. 2016 Jun;8(6):677-9. doi: 10.2217/imt.16.6.
3
Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?黑色素瘤中免疫检查点抑制剂联合疗法：毒性是否值得？
IFN-α2b在恶性肿瘤治疗中的直接和间接作用：既是射手也是箭。
Biomark Res. 2022 Sep 14;10(1):69. doi: 10.1186/s40364-022-00415-y.
4
Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy-An Integrated View into Other Neoplasms and Chemokine Networks.白细胞介素-8在黑色素瘤发病机制、预后及治疗中的作用——对其他肿瘤和趋化因子网络的综合观点
Cells. 2021 Dec 30;11(1):120. doi: 10.3390/cells11010120.
5
Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways.I 型干扰素（IFN）调节的经典和非经典信号通路的激活。
Front Immunol. 2020 Nov 23;11:606456. doi: 10.3389/fimmu.2020.606456. eCollection 2020.
6
Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma.干扰素-α1b（IFN-α1b）对肿瘤免疫反应的影响：解释 IFN-α1b 治疗黑色素瘤疗效显著的原因。
Med Sci Monit. 2020 Mar 14;26:e922790. doi: 10.12659/MSM.922790.
Rev Recent Clin Trials. 2016;11(2):81-6. doi: 10.2174/1574887111666160330120712.
4
Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.阳光地带黑色素瘤试验的最终结果：一项多机构前瞻性随机III期研究，评估辅助性高剂量干扰素α-2b及前哨淋巴结活检分期患者的根治性淋巴结清扫术的作用。
J Clin Oncol. 2016 Apr 1;34(10):1079-86. doi: 10.1200/JCO.2015.63.3776. Epub 2016 Feb 8.
5
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.EORTC 18952试验对IIB-III期皮肤黑色素瘤切除患者辅助治疗的长期随访：比较中等剂量α-2b干扰素（IFN）与观察结果，发现原发灶溃疡是IFN敏感性的关键决定因素。
Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.
6
Adjuvant Therapy of Melanoma.黑色素瘤的辅助治疗
Cancer Treat Res. 2016;167:181-208. doi: 10.1007/978-3-319-22539-5_7.
7
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
8
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.纳武利尤单抗对比化疗用于 CTLA-4 治疗后进展的晚期黑色素瘤患者（CheckMate 037）：一项随机、对照、开放标签、III 期临床试验。
Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
9
Ipilimumab and its toxicities: a multidisciplinary approach.依匹木单抗及其毒性：一种多学科方法。
Oncologist. 2013 Jun;18(6):733-43. doi: 10.1634/theoncologist.2012-0483. Epub 2013 Jun 17.
10
Melanoma immunotherapy: historical precedents, recent successes and future prospects.黑色素瘤免疫疗法：历史先例、近期成功和未来前景。
Immunotherapy. 2013 Feb;5(2):169-82. doi: 10.2217/imt.12.162.